Michael C. Wei
Impact in
- Molecular Biology top 0.5%
- Cell death mechanisms and regulation
- Mitochondrial Function and Pathology
- RNA Interference and Gene Delivery
- ATP Synthase and ATPases Research
- Oncology top 1%
- Cancer-related Molecular Pathways
- CAR-T cell therapy research
Papers in
- Oncology 43
- CAR-T cell therapy research 28
-
- Lymphoma Diagnosis and Treatment 32
- Co-authors
- Stanley J. Korsmeyer (6 shared papers)Tullia Lindsten (3 shared papers)Solly Weiler (4 shared papers)Emily H. Cheng (2 shared papers)Atan Gross (3 shared papers)Jennifer Jockel (2 shared papers)Kevin A. Roth (1 shared paper)Grant R. MacGregor (1 shared paper)
- Journals
- Blood (25 papers)Journal of Clinical Oncology (8 papers)Blood Advances (4 papers)Cancer Research (3 papers)Science (2 papers)
- Partner nations
- United StatesCanadaAustralia
In The Last Decade
Michael C. Wei
78 papers receiving 11.0k citations
Michael C. Wei's Hit Papers
Peers
Comparison fields: 5 of 172
- Molecular Biology 7.7k
- Oncology 2.2k
- Immunology 1.6k
- Cancer Research 928
- Cell Biology 1.0k
Countries citing papers authored by Michael C. Wei
This map shows the geographic impact of Michael C. Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael C. Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael C. Wei more than expected).
Fields of papers citing papers by Michael C. Wei
This network shows the impact of papers produced by Michael C. Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael C. Wei. The network helps show where Michael C. Wei may publish in the future.
Co-authors
The 25 scholars most cited alongside Michael C. Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 85 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death Hit paper breakdown → | 2001 | 3290 |
| 2 | BCL-2, BCL-XL Sequester BH3 Domain-Only Molecules Preventing BAX- and BAK-Mediated Mitochondrial Apoptosis Hit paper breakdown → | 2001 | 1391 |
| 3 | tBID, a membrane-targeted death ligand, oligomerizes BAK to release cytochrome c Hit paper breakdown → | 2000 | 1051 |
| 4 | Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis Hit paper breakdown → | 1998 | 935 |
| 5 | Caspase Cleaved BID Targets Mitochondria and Is Required for Cytochrome c Release, while BCL-XL Prevents This Release but Not Tumor Necrosis Factor-R1/Fas Death Hit paper breakdown → | 1999 | 876 |
| 6 | Pro-apoptotic cascade activates BID, which oligomerizes BAK or BAX into pores that result in the release of cytochrome c Hit paper breakdown → | 2000 | 832 |
| 7 | 2000 | 467 | |
| 8 | Occupancy-driven energy management for smart building automation Hit paper breakdown → | 2010 | 427 |
| 9 | Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study Hit paper breakdown → | 2022 | 275 |
| 10 | 1997 | 234 | |
| 11 | 1996 | 150 | |
| 12 | 2019 | 145 | |
| 13 | 2015 | 104 | |
| 14 | Transduced p16INK4a peptides inhibit hypophosphorylation of the retinoblastoma protein and cell cycle progression prior to activation of Cdk2 complexes in late G1. | 1999 | 97 |
| 15 | 2018 | 57 | |
| 16 | 2013 | 57 | |
| 17 | 1999 | 50 | |
| 18 | 2023 | 48 | |
| 19 | 2023 | 46 | |
| 20 | 2024 | 45 |
About Michael C. Wei
Michael C. Wei is a scholar working on Oncology, Pathology and Forensic Medicine, Molecular Biology, Genetics and Radiology, Nuclear Medicine and Imaging, having authored 85 papers that have together received 11.2k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (32 papers), CAR-T cell therapy research (28 papers), Chronic Lymphocytic Leukemia Research (18 papers), Monoclonal and Polyclonal Antibodies Research (16 papers), Cell death mechanisms and regulation (10 papers), Biosimilars and Bioanalytical Methods (8 papers), Cutaneous lymphoproliferative disorders research (8 papers) and Acute Lymphoblastic Leukemia research (6 papers). The work is most often cited by research in Molecular Biology (7.7k citations), Oncology (2.2k citations), Immunology (1.6k citations), Cancer Research (928 citations) and Cell Biology (1.0k citations). Michael C. Wei has collaborated with scholars based in United States, Canada and Australia. Frequent co-authors include Stanley J. Korsmeyer, Tullia Lindsten, Solly Weiler, Emily H. Cheng, Atan Gross, Jennifer Jockel, Kevin A. Roth, Grant R. MacGregor, Craig B. Thompson and Andrea J. Ross. Their work appears in journals such as Blood, Journal of Clinical Oncology, Blood Advances, Cancer Research and Science.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.